Design Therapeutics, Inc.
DSGN
Positions held
Your positionsDSGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $719.06M | Enterprise value | $514.33M | Trailing P/E | — | Forward P/E | -7.10 |
| PEG | — | Price / book | 3.56 | Beta | 1.69 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -34.1% | ROA | -22.5% | Debt / equity | 0.01 |
| Current ratio | 18.86 | Free cash flow | -$32.36M | Analyst recommendation | strong_buy | Mean target | $21.71 |
| 52w high | $17.25 | 52w low | $5.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$20.2M | -$17.6M | -$16.0M | -$17.0M | -$19.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.2M | -$19.7M | -$18.2M | -$19.3M | -$21.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | — |
Headlines — positive tone
• [OK · fundamentals] Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
News
2026-10-02 · Nike downgraded, Airbnb upgraded: Wall Street's top analyst calls
2026-10-02 · Wells Fargo Initiates Design Therapeutics at Overweight With $26 Price Target
2026-09-02 · Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
2026-08-27 · Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
2026-08-03 · Design Therapeutics Q2 Net Loss Narrows
2026-08-03 · Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns